Evaluation of OxxyneaGS in Acute Glycemic Regulation on Light Hyperglycemic Subjects
OxxyneaGS: Single Blinded Randomized Study
1 other identifier
interventional
10
1 country
1
Brief Summary
This study aims to evaluate and select the best combination of polyphenol and white kidney bean ingredients in the acute glycemic modulation after a complete meal by measuring blood glucose and insulin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 28, 2021
CompletedFirst Posted
Study publicly available on registry
June 4, 2021
CompletedStudy Start
First participant enrolled
June 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2022
CompletedAugust 10, 2022
August 1, 2022
11 months
May 28, 2021
August 9, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Acute change in glycemia in response to a meal, by measuring glucose concentration in the blood at different time points
8 hours
Secondary Outcomes (3)
Lipid profile evolution after a meal
8 hours
Oxxidative stress variation after a meal, measured by oxidized/reduced glutathione (GSH/GSSG)
8 hours
Acute change in insulinemia in response to a meal, by measuring insulin concentration in the blood at different time points
8 hours
Study Arms (17)
Verum T1
PLACEBO COMPARATORVerum T2
EXPERIMENTALVerum T3
EXPERIMENTALVerum T4
EXPERIMENTALVerum T5
EXPERIMENTALVerum T6
EXPERIMENTALVerum T7
EXPERIMENTALVerum T8
EXPERIMENTALVerum T9
EXPERIMENTALVerum T10
EXPERIMENTALVerum T11
EXPERIMENTALVerum T12
EXPERIMENTALVerum T13
EXPERIMENTALVerum T14
EXPERIMENTALVerum T15
EXPERIMENTALVerum T16
EXPERIMENTALVerum T17
PLACEBO COMPARATORInterventions
Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Eligibility Criteria
You may qualify if:
- Glycemia: 100-125mg/dL
- Both sexes
- Overweight BMI range (27-32)
- Age: 20-50 years old
You may not qualify if:
- Metabolic/Chronical disease
- Menopausal women
- Being pregnant, breastfeeding or wanting to have a baby
- Former obese with a history of yoyo effect
- Have been involved in a weight loss program in the past 12 months or subjected to weight reduction surgery
- Having started or quit smoking, having a high alcohol consumption
- Have in the past been in a long-term antibiotherapy (1 month or more) and/or a regular antibiotherapy in the past 12 months
- Allergy to olive, artichoke, black currant, grapefruit, grape, white kidney bean, olive, pomegranate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fytexialead
Study Sites (1)
UCAM
Murcia, 30107, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pedro Alcaraz Ramon
UCAM
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 28, 2021
First Posted
June 4, 2021
Study Start
June 15, 2021
Primary Completion
April 30, 2022
Study Completion
May 30, 2022
Last Updated
August 10, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share